Literature DB >> 7884661

Decomposition of clozapine N-oxide in the qualitative and quantitative analysis of clozapine and its metabolites.

G Lin1, G McKay, J W Hubbard, K K Midha.   

Abstract

Pooled plasma from healthy volunteers was spiked with pure, synthetic clozapine or clozapine N-oxide and then made alkaline with either sodium hydroxide or sodium carbonate. The alkalized samples were allowed to stand at room temperature for various time intervals before extraction with organic solvent and then analyzed by high-performance liquid chromatography. It was found that clozapine N-oxide was reduced to clozapine in plasma made alkaline with sodium hydroxide, but such reduction was negligible in the plasma made alkaline with sodium carbonate. The amount of clozapine produced from clozapine N-oxide depended upon both the strength of the alkali added to the plasma and the duration of exposure of the plasma proteins plus clozapine N-oxide to the alkali. The reduction appears to take place through reducing equivalents generated by the action of strong alkali on plasma proteins. The thermal lability of clozapine N-oxide during gas chromatography-mass spectrometric analysis was also investigated. It was found that clozapine N-oxide was quantitatively decomposed to clozapine during gas chromatography-mass spectrometric analysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7884661     DOI: 10.1002/jps.2600831010

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  7 in total

1.  Comparability of whole-blood and plasma clozapine and norclozapine concentrations.

Authors:  R J Flanagan; B Yusufi; T R E Barnes
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

2.  CNO Evil? Considerations for the Use of DREADDs in Behavioral Neuroscience.

Authors:  Stephen V Mahler; Gary Aston-Jones
Journal:  Neuropsychopharmacology       Date:  2018-02-07       Impact factor: 7.853

3.  Pathway-specific inhibition of critical projections from the mediodorsal thalamus to the frontal cortex controls kindled seizures.

Authors:  Evan Wicker; Safwan K Hyder; Patrick A Forcelli
Journal:  Prog Neurobiol       Date:  2022-05-12       Impact factor: 10.885

Review 4.  Clozapine plasma level monitoring: current status.

Authors:  T B Cooper
Journal:  Psychiatr Q       Date:  1996

5.  Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.

Authors:  G Schaber; I Stevens; H J Gaertner; K Dietz; U Breyer-Pfaff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

6.  Pharmacokinetic and pharmacodynamic actions of clozapine-N-oxide, clozapine, and compound 21 in DREADD-based chemogenetics in mice.

Authors:  Martin Jendryka; Monika Palchaudhuri; Daniel Ursu; Bastiaan van der Veen; Birgit Liss; Dennis Kätzel; Wiebke Nissen; Anton Pekcec
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

7.  Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.

Authors:  Duncan A A MacLaren; Richard W Browne; Jessica K Shaw; Sandhya Krishnan Radhakrishnan; Prachi Khare; Rodrigo A España; Stewart D Clark
Journal:  eNeuro       Date:  2016-11-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.